StockMirror — Stock Screener

DRREDDY Q1 FY27 Results & Earnings Analysis

Sentiment: Neutral (Confidence: high)

Earnings Summary

Dr. Reddy's Q1FY27 was sharply impacted by a ₹240 cr semaglutide API provision and lower lenalidomide sales, causing a 5.6% YoY revenue decline and EBITDA margin of 12.5%. However, the underlying base business grew double-digit across all regions (NA, India, Emerging Markets). Management expects a strong H2 recovery with semaglutide resumption by November, targeting a ~20% EBITDA margin ex-semaglutide. Key catalysts: abatacept approval (Dec 2026), new US launches, and cost productivity. Risks: semaglutide API fix execution, Middle East conflict, and US generic pricing pressure. , ,

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management balanced focus: targeting double-digit revenue growth while maintaining 'neighbourhood of 20%' EBITDA margin ex-semaglutide, and guiding for low single-digit cost growth vs. double-digit sales growth. They aim to grow branded markets (52% of revenue) which provide stable margins. ,

About Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited (DRREDDY) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More